SGMT
Sagimet Biosciences Inc.
1W: +13.0%
1M: -8.6%
3M: -11.5%
YTD: -12.7%
1Y: +41.0%
$5.32
+0.08 (+1.53%)
After Hours: $5.17 (-0.16, -2.91%)
Weekly Expected Move ±9.0%
$4
$4
$5
$5
$6
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$170.3M
52W Range1.73-11.41
Volume145,933
Avg Volume568,912
Beta3.21
Dividend—
Analyst Ratings
Company Info
CEODavid A. Happel
Employees14
SectorHealthcare
IndustryBiotechnology
IPO Date2023-07-17
Websitesagimet.com
155 Bovet Road
San Mateo, CA 94402
US
San Mateo, CA 94402
US
650-561-8600
About Sagimet Biosciences Inc.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Latest News
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of “Moderate Buy” from Analysts
HC Wainwright Has Negative Outlook for SGMT FY2027 Earnings
Q1 Earnings Forecast for SGMT Issued By HC Wainwright
Sagimet Biosciences GAAP EPS of -$0.29
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Chauche Thierry | A-Award | 44,000 | — | 2026-02-19 |
| Chauche Thierry | A-Award | 88,000 | $5.38 | 2026-02-19 |
| Rozek Elizabeth | A-Award | 44,000 | — | 2026-02-19 |
| Rozek Elizabeth | A-Award | 88,000 | $5.38 | 2026-02-19 |
| Martins Eduardo Brun | A-Award | 44,000 | — | 2026-02-19 |